Rivastigmine in the treatment of Sleep REM Behaviour Disorder (RBD) and Hallucinations in Parkinsonism: a Clinical and Polysomnographic study.

Trial Profile

Rivastigmine in the treatment of Sleep REM Behaviour Disorder (RBD) and Hallucinations in Parkinsonism: a Clinical and Polysomnographic study.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2012

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Hallucinations; Parkinsonian disorders; Sleep disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Mar 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 30 Jan 2012 Primary endpoint 'REM-sleep' has been met according to results published in Movement Disorders.
    • 30 Jan 2012 Results published in Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top